lobbying_activities: 834262

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
834262	4a3a28e4-bd91-4681-b34b-71e59ad2806b	Q3	TARPLIN STRATEGIES LLC	40032282	GENENTECH, INC.	2009	third_quarter	PHA	H.R. 1548, the Pathway for Biosimilars Act, FDA approval of follow-on biologics. H.R. 1427 and S. 726, the Promoting Innovation and Access to Life-Saving Medicine Act, FDA approval of follow-on biologics. H.R. 3200, America's Affordable Health Choices Act - FDA approval of follow-on biologics and length of data exclusivity period. S. 1679, the Affordable Health Choices Act - FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program. Senate Finance Committee Chairman's Mark, America's Healthy Future Act - Medicare and Medicaid reimbursement issues, possible taxes and fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. S. 1232, the Pharmaceutical Market Access and Drug Safety Act, importation of prescription drugs.	Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE	75000		0	0	2009-10-18T15:40:26-04:00